XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Class R Redeemable Stock
Common Stock
Common Class A
Common Stock
Common Class B
Common Stock
Class R Redeemable Stock
Deferred Shares
Additional Paid-In Capital
Unitholders’/ Shareholders’ Contributions
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income/(Loss)
Non-Controlling Interest
Treasury Interests
Beginning balance (in shares) at Dec. 31, 2018       0 0 0 0              
Beginning balance at Dec. 31, 2018 $ 4,552,079     $ 0 $ 0 $ 0 $ 0 $ 0 $ 3,282,516 $ 1,215,953   $ (10,255) $ 63,865 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Distributions (880,142)                 (739,276)     (140,866)  
Net income (loss) 2,461,419                 2,348,535     112,884  
Unrealized gains on available for sale debt securities 6,159                     6,159    
Reclassification of loss on interest rate swaps 6,189                     6,189    
Purchase of treasury interests $ (4,266)                         (4,266)
Accounting standards update [Extensible List] Accounting Standards Update 2016-13 [Member]                          
Reclassification of unrealized gains on available for sale debt securities $ 0                          
Ending balance (in shares) at Dec. 31, 2019       0 0 0 0              
Ending balance at Dec. 31, 2019 6,141,438 $ (192,705)   $ 0 $ 0 $ 0 $ 0 0 3,282,516 2,825,212 $ (192,705) 2,093 35,883 (4,266)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Distributions (1,105,765)                 (313,408)     (792,357)  
Net income (loss) 1,701,954                          
Unrealized gains on available for sale debt securities 83,120                     60,617 22,503  
Reclassification of loss on interest rate swaps 4,066                     4,066    
Contributions 1,482,322               307,646       1,174,676  
Transfer of interests 0               (1,037,161)       1,037,161  
Initial share issuance upon registration of Royalty Pharma plc (in shares)           50                
Initial share issuance upon registration of Royalty Pharma plc 63         $ 63                
Issuance of Class B shares to Continuing Investor Partnerships (in shares)         535,383                  
Issuance of Class B ordinary shares to Continuing Investors Partnerships 1       $ 1                  
Effect of exchange by Continuing Investors of Class B shares for Class A shares and reallocation of historical equity (in shares)       294,176 (294,176)   294,176              
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (1)     $ 30 $ (1)     1,402,762 (2,553,001) (1,261,014)   (24,022) 2,433,098 2,147
Issuance of Class A ordinary shares sold in initial public offering, net of offering costs (in shares)       71,652                    
Issuance of Class A ordinary shares sold in IPO, net of offering costs 1,908,744     $ 7       1,150,383         758,354  
Share based compensation and related issuance of Class A ordinary shares (in shares)       76                    
Share-based compensation and related issuances of Class A ordinary shares 5,428             5,428            
Other exchanges (in shares)       22,231 (22,231)   22,231              
Other exchanges 191     $ 2       307,391       2,562 (309,566) (198)
Dividends (112,490)                 (112,490)        
Reclassification of unrealized gains on available for sale debt securities (20,551)                     (10,921) (9,630)  
Ending balance (in shares) at Dec. 31, 2020       388,135 218,976 50 316,407              
Ending balance at Dec. 31, 2020 9,895,815     $ 39 $ 0 $ 63 $ 0 2,865,964 0 1,920,635   34,395 5,077,036 (2,317)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Distributions (614,973)                       (614,973)  
Net income (loss) 1,241,201                 619,728     621,473  
Unrealized gains on available for sale debt securities 11,600                     6,335 5,265  
Reclassification of loss on interest rate swaps 0                          
Contributions 48,539                       48,539  
Share based compensation and related issuance of Class A ordinary shares (in shares)       65                    
Share-based compensation and related issuances of Class A ordinary shares 2,443             2,443            
Other exchanges (in shares)       44,763 (44,763)   44,763              
Other exchanges 0     $ 4       639,126       4,242 (642,974) (398)
Dividends (285,184)                 (285,184)        
Reclassification of unrealized gains on available for sale debt securities (50,896)                     (28,481) (22,415)  
Ending balance (in shares) at Dec. 31, 2021     50 432,963 174,213 50 361,170              
Ending balance at Dec. 31, 2021 $ 10,248,545     $ 43 $ 0 $ 63 $ 0 $ 3,507,533 $ 0 $ 2,255,179   $ 16,491 $ 4,471,951 $ (2,715)